The Gabrail Cancer Center currently has many Clinical Trial opportunities . For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or via email CSmith@GabrailCancerCenter.com.
A PHASE 1 FIRST-IN HUMAN, MULTI-CENTER, OPEN LABEL DOSE-ESCALATION STUDY TO DETERMINE THE SAFETY, TOLERABILITY PHARMACOKINETICS AND RP2D OF ABBV-184 AS A SINGLE AGENT IN SUBJECTS WITH PREVIOUSLY TREATED CANCERS
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)
A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle as Monotherapy or in Combination inTreatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy
AN OPEN-LABEL COMPASSIONATE USE TRAIL OF UBLITUXIMAB AND/OR UMBRALISIB (TGR-1202) IN COMBINATION WITH OTHER NOVEL AGENTS OR AS SINGLE AGENTS IN SUBJECTS CURRENTLY RECEIVING TREATMENT ON A TG THERAPEUTICS STUDY
A PHASE IB/II STUDY OF APG-2575 AS A SINGLE AGENT OR IN COMBINATION WITH OTHER THERAPEUTICS AGENTS IN PATIENTS WITH RELAPSED AND/OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) (SACRED)
A PHASE 1B STUDY OF THE PHARMACOKINETICS, SAFETY AND EFFICACY OF ORALLY ADMINISTERED HQP1351 IN SUBJECTS WITH REFRACTORY CHRONIC MYELOID LEUKEMIA (CML)
An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Return to Clinical Trials at GCC
